Prescription medicine

Triclabendazole Brand names: Egaten

Triclabendazole (Egaten) is a prescription medicine with an FDA approval on record since 2019. No generic is listed in FDA's NDC Directory.

No generic listed

Check it at the source: the triclabendazole FDA label on DailyMed (effective June 4, 2026, Novartis Pharmaceuticals Corporation); the NDA 208711 record on Drugs@FDA; every triclabendazole label on DailyMed.

Highlights of the record

FDA label of June 4, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026

Used for

From the label: indications and usage
EGATEN ® is indicated for the treatment of fascioliasis in patients 6 years of age and older.

Forms and strengths

250 mg

Tablet.

On the market

Earliest approval on file: February 13, 2019 Egaten, Novartis; Drugs@FDA’s file, where older or withdrawn approvals can be missing
Generic approvals: No generic approved
Labelers listed (NDC): 1 of which 0 under generic applications, 1 under brand applications, repackagers included

Supply and safety

Pharmacy cost (NADAC): Not in the survey
Shortage (FDA): No current entry
Recalls by its makers (FDA): No recall recorded
FAERS reports: 44 through July 30, 2026

What is triclabendazole used for?

From the label: indications and usage
EGATEN ® is indicated for the treatment of fascioliasis in patients 6 years of age and older. EGATEN ® tablet is an anthelmintic indicated for the treatment of fascioliasis in patients 6 years of age and older.

FDA pharmacologic class: Anthelmintic.

Source: FDA drug label (EGATEN), Novartis Pharmaceuticals Corporation, effective June 4, 2026 (SPL set 5552884e-10ea-450c-9658-d3d4f33c946e), via openFDA; the full label on DailyMed

Is there a generic for triclabendazole (Egaten)?

No generic triclabendazole is approved (Drugs@FDA, October 8, 2026).

2019 earliest approval on file

Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)

What do FAERS reports show for triclabendazole?

The FDA Adverse Event Reporting System holds 44 reports that list triclabendazole among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 5 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

The most reported reactions

Malaise7
Trematode Infection5
Fascioliasis (a use or a product term, not a reaction)4
Condition Aggravated (a use or a product term, not a reaction)3
Illness3
Nausea (named in the label)3
Overdose (a use or a product term, not a reaction)3
Rash3

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026

What next?

Other anthelmintics: the pharmacologic class, with prices and generics
Triclabendazole side effects: the label's list beside FAERS reports
Check an interaction: what two or more labels say about each other